Ahrens Michael, Tsantrizos Anthony, Donkersloot Peter, Martens Frederic, Lauweryns Philippe, Le Huec Jean Charles, Moszko Slawomir, Fekete Zsolt, Sherman John, Yuan Hansen A, Halm Henry
Clinic for Spine Surgery with Scoliosis Center, Klinikum Neustadt, Academic Teaching Hospital of University of Schleswig-Holstein, Campus Luebeck, Germany.
Spine (Phila Pa 1976). 2009 Jun 1;34(13):1376-84. doi: 10.1097/BRS.0b013e3181a3967f.
A prospective, nonrandomized multicenter study of lumbar disc nucleus replacement using the DASCOR Disc Arthroplasty Device. An interim analysis of clinical results is presented, obtained from European patients enrolled in 2 studies.
To determine the safety and efficacy of the DASCOR Device for the treatment of symptomatic single-level degenerative disc disease (DDD).
Patients suffering from DDD have been limited to a choice between nonoperative therapies or invasive surgical treatments such as total disc replacement or spinal fusion. The DASCOR Device was developed to provide an alternative treatment with a less invasive surgical intervention.
A total of 85 patients from 11 European centers were enrolled in 1 of 2 studies between February 2003 and July 31, 2007. Data were collected before surgery and after surgery at 6 weeks and at 3, 6, 12, and 24 months. The clinical outcome measures were obtained from the Visual Analog Scale (VAS) for back pain, the Oswestry Disability Index (ODI), radiographic assessments, and records of analgesic medication use.
Mean VAS and ODI scores improved significantly after 6 weeks and throughout the 2 years. Radiographic results demonstrated, at a minimum, maintenance of disc height with no device expulsion and, despite Modic-Type 1 changes, no subsidence. Fourteen patients had serious adverse events including device explants in 7 patients (7 of 85), in which the main complication was resumed back pain after time. Patients' rate of analgesic medication decreased dramatically over time, with all patients experiencing significant improvements after 3 months and nearly no analgesic medication or narcotic drug use at 2 years.
The interim outcomes showed significant improvements in mean ODI and VAS scores. The results of these European studies suggest that the DASCOR Device may be a safe and effective less-invasive surgical option for patients with DDD.
一项使用DASCOR椎间盘置换装置对腰椎间盘髓核置换进行的前瞻性、非随机多中心研究。本文呈现了对临床结果的中期分析,这些结果来自参与两项研究的欧洲患者。
确定DASCOR装置治疗有症状的单节段退变性椎间盘疾病(DDD)的安全性和有效性。
患有DDD的患者在非手术治疗或侵入性手术治疗(如全椎间盘置换或脊柱融合)之间的选择有限。开发DASCOR装置是为了提供一种侵入性较小的手术干预替代治疗方法。
2003年2月至2007年7月31日期间,来自11个欧洲中心的85名患者参加了两项研究中的一项。在手术前、术后6周以及术后3、6、12和24个月收集数据。临床结果指标来自于背痛视觉模拟量表(VAS)、Oswestry功能障碍指数(ODI)、影像学评估以及止痛药物使用记录。
6周后及整个2年期间,平均VAS和ODI评分显著改善。影像学结果显示,至少维持了椎间盘高度,没有装置脱出,尽管有Modic 1型改变,但没有下沉。14名患者出现严重不良事件,包括7名患者(85名中的7名)的装置取出,其中主要并发症是一段时间后背痛复发。随着时间推移,患者的止痛药物使用率大幅下降,所有患者在3个月后均有显著改善,2年时几乎不再使用止痛药物或麻醉药物。
中期结果显示平均ODI和VAS评分有显著改善。这些欧洲研究的结果表明,DASCOR装置对于DDD患者可能是一种安全有效的侵入性较小的手术选择。